Skin melanoma: causes and main treatment approaches

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Skin melanoma is one of the most common types of cancer in the world, and the incidence rate continues to grow in many regions. The main risk factor for the development of this disease remains exposure to ultraviolet (UV) radiation, for example, with prolonged exposure to the sun. In addition to damage caused by UV radiation, the development of melanoma is also associated with certain hereditary and acquired genetic changes. The stage of skin melanoma at the time of diagnosis is a key prognostic factor, which is typical for most malignant neoplasms. The development of skin melanoma is facilitated by context-dependent genetic mutations that either weaken tumor suppression mechanisms or activate signaling pathways that stimulate their growth. In addition to external factors such as exposure to ultraviolet radiation, the tumor microenvironment can have a significant impact on the progression, invasive growth and metastasis of melanoma. Malignant melanoma can arise from both benign nevi and de novo – without previous formations. Diagnosis of this disease can be difficult due to the wide variety of precancerous melanocytic changes. Molecular markers and gene expression profiles come to the aid of doctors, facilitating a more accurate definition of the pathology. Since skin melanoma is one of the most metastatic cancers in humans, its early detection opens up the possibility of effective treatment. This creates a need for more accurate methods for predicting the course of the disease, which can be based on modern genetic tests. Treatment of patients at early stages, as well as their subsequent follow-up, play a key role in improving the quality of life of patients and improving long-term treatment results.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Luisa Yusupova

Kazan State Medical Academy – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Хат алмасуға жауапты Автор.
Email: yuluizadoc@hotmail.com
ORCID iD: 0000-0001-8937-2158
SPIN-код: 5743-6872

Dr. Sci. (Med.), Professor, Head of the Department of Dermatovenereology and Cosmetology

Ресей, Kazan

Rustem Khasanov

Kazan State Medical Academy – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: ksma.rf@kgma.info
ORCID iD: 0000-0003-4107-8608
SPIN-код: 9198-5989

Director, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Oncology, Radiology and Palliative Medicine

Ресей, Kazan

Luiza Karpenko

Kazan State Medical Academy – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: klg5@mail.ru
ORCID iD: 0000-0002-3972-9101
SPIN-код: 1304-6810

Cand. Sci. (Med.), Associate Professor, Department of Oncology, Radiology and Palliative Medicine

Ресей, Kazan

Ilgiz Gataullin

Kazan State Medical Academy – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: ilgizg@list.ru
ORCID iD: 0000-0001-5115-6388
SPIN-код: 3049-2957

Dr. Sci. (Med.), Professor, Department of Oncology, Radiology and Palliative Medicine

Ресей, Kazan

Zinaida Afanasieva

Kazan State Medical Academy – Branch Campus of the Russian Medical Academy of Continuous Professional Education

Email: z-afanasieva@mail.ru
ORCID iD: 0000-0002-6187-2983
SPIN-код: 9921-0860

Dr. Sci. (Med.), Professor of the Department of Oncology, Radiology and Palliative Medicine

Ресей, Kazan

Әдебиет тізімі

  1. Eggermont A.M.M., Robert C., Spatz A. Cutaneous melanoma. Lancet. 2014;383:816–827. https://dx.doi.org/10.1016/S0140-6736(13)60802-8
  2. Юсупова Л.А., Карпенко Л.Г., Афанасьева З.А., Сигал Е.И. Меланома: вопросы диагностики и лечения. Казань. 2023. [Yusupova L.A., Karpenko L.G., Afanas’eva Z.A., Sigal E.I. Melanoma: issues of diagnosis and treatment. Kazan. 2023. (In Russ.)].
  3. Garbe C., Peris K., Hauschild A., Saiag P. European consensus-based interdisciplinary guideline - Update 2016. Eur J Cancer. 2016;63:201–217. https://dx.doi.org/10.1016/j.ejca.2016.05.005
  4. Сергеев Ю.Ю., Мордовцева В.В., Сергеев В.Ю. Меланома кожи в практике дерматолога. Фарматека. 2017;17:671–72. [Sergeev Yu.Yu., Mordovceva V.V., Sergeev V.Yu. Skin melanoma in practice of dermatologist. Farmateka. 2017;17:67–72. (In Russ.)].
  5. Whiteman D.C., Green A.C., Olsen C.M. The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031. J Invest Dermatol. 2016;136(6):1161–1171. https://dx.doi.org/10.1016/j.jid.2016.01.035
  6. Юсупова Л.А. Современный взгляд на проблему старения кожи. Лечащий врач. 2017;6:75. [Yusupova L.A. Modern view on the problem of skin aging. Lechashchii vrach. 2017;6:75. (In Russ.)].
  7. Гилязутдинов И.А., Хасанов Р.Ш., Сафин И.Р., Моисеев В.Н. Злокачественные опухоли мягких тканей и меланома кожи. М., 2010. [Gilyazutdinov I.A., Hasanov R.Sh., Safin I.R., Moiseev V.N. Malignant tumors of soft tissues and melanoma of the skin. M., 2010. (In Russ.)].
  8. Меланома кожи и слизистых оболочек. Клинические рекомендации. М., 2022. 137 с. [Melanoma of the skin and mucous membranes. Clinical guidelines. M., 2022. (In Russ.)].
  9. Karimkhani S., Green A.S., Naisten T. et al. Global burden of melanoma: results of the Global Burden of Disease study 2015. Br J Dermatol. 2017;177(1):134–140. https://dx.doi.org/10.1111/bjd.15510
  10. Quek C. Genetics and gnomics of melanoma: current progress and future directions. Genes (Basel). 2023;14(1): 232. https://dx.doi.org/10.3390/genes14010232
  11. Timar J., Vizkeleti L.Э Doma V. et al. Genetic progression of malignant melanoma. Cancer Metastasis Rev. 2016;35(1):93–107. https://dx.doi.org/10.1007/s10555-016-9613-5
  12. Low M.H., McGregor S., Hayward N.K. The genetics of melanoma: recent findings take us beyond well-studied pathways. J. Investiga. Dermatol. 2012;132(7):1763–1774. https://dx.doi.org/10.1038/jid.2012.75
  13. Amos K.I., Wang L.E., Li J.E. et al. A genome-wide association study identifies new loci predisposing to skin melanoma. Hum Mol Genet. 2011;20(24):5012–5023. https://dx.doi.org/10.1093/hmg/ddr415
  14. Barrett J.H., Iles M.M., Harland M. et al. A genome-wide association study identifies three new loci of susceptibility to melanoma. Nat Genet. 2011;43(11):1108–1113. https://dx.doi.org/10.1038/ng.959
  15. Jager M.J., Shields K.L., Sebulla K.M. et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24. https://dx.doi.org/10.1038/s41572-020-0158-0
  16. Doma V., Barbai T., Belau M.A. et al. KIT mutation rate and melanoma structure in Central and Eastern Europe. Patol Oncol Resolution. 2020;26(1):17–22. https://dx.doi.org/10.1007/s12253-019-00788-w
  17. Cancer Genome Atlas network. Genomic classification of skin melanoma. Cell. 2015;161(7):1681–1696. https://dx.doi.org/10.1016/j.cell.2015.05.044
  18. Ordonez N.G. The importance of immunohistochemical markers associated with melanocytes in the diagnosis of malignant melanoma. Hum Pathol. 2014;45(2):191–205. https://dx.doi.org/10.1016/j.humpath.2013.02.007
  19. Deacon D.K., Smith E.A., Judson-Torres R.L. Molecular biomarkers for screening, diagnosis, and prognosis of melanoma: current status and future directions. Front Med. 2021;8:642380. https://dx.doi.org/10.3389/fmed.2021.642380
  20. Clark L.E., Flake D.D., Busam K. et al. Independent validation of the gene expression signature for differentiation of malignant melanoma from benign melanocytic nevi. Cancer. 2017;123(4):617–628. https://dx.doi.org/10.1002/cncr.30385
  21. Reimann J.D.R., Salim S., Velasquez E.F. et al. Comparison of melanoma gene expression index with histopathology, FISH and SNP array for classification of melanocytic neoplasms. Mod Pathol. 2018;31(11):1733–1743. https://dx.doi.org/10.1038/s41379-018-0087-6
  22. Timar J, Ladanyi A. Molecular pathology of skin melanoma: epidemiology, differential diagnostics, prognosis and therapy prediction. Int J Mol Sci. 2022;23(10):5384. https://dx.doi.org/10.3390/ijms23105384
  23. Garbe C., Amaral T., Peris K. et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J Cancer. 2022;170:236–255. https://dx.doi.org/10.1016/j.ejca.2022.03.008
  24. Menzies S., Barry R., Ormond P. Multiple primary melanoma: a retrospective review of a single center. Melanoma Res. 2017;27(6):638–640. https://dx.doi.org/10.1097/CMR.0000000000000395
  25. Trotter S.K., Sroa N., Winkelman R.R. et al. A global review of recommendations for follow-up treatment of melanoma. J Clin Aesthet Dermatol. 2013;6(9):18–26.
  26. Ferrone K.R., Ben Porat L., Panageas K.S. et al. Clinical and pathological features and risk factors of multiple primary melanomas. JAMA. 2005;294(13):1647–1654. https://dx.doi.org/10.1001/jama.294.13.1647
  27. Moore M.M., Geller A.C., Warton E.M. et al. Multiple primary melanomas among 16,570 melanoma patients diagnosed at Kaiser Permanente in Northern California, from 1996 to 2011. J Am Acad Dermatol. 2015;73(4):630–636. https://dx.doi.org/10.1016/j.jaad.2015.06.059
  28. Gassenmaier M., Stec T., Keim U. et al. Frequency and characteristics of thick second primary melanoma: a study of the central malignant melanoma Registry. J Eur Acad Dermatol Venereol. 2019;33(1):63–70. https://dx.doi.org/10.1111/jdv.15194
  29. Ackerman D.M., Dieng M., Medcalf E. et al. Assessment of the development potential of specialist-led follow-up after treatment of localized melanoma (MEL-SELF): a pilot randomized clinical trial. JAMA Dermatol. 2021;158(1):33–42. https://dx.doi.org/10.1001/jamadermatol.2021.4704
  30. Goldstein A.M., Tucker M.A. Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev. 2013;22(4):528-32. https://dx.doi.org/10.1158/1055-9965.EPI-12-1346
  31. Kruiff S., Hoekstra H.J. The current status of S-100B as a biomarker in melanoma. Eur J Surg Oncol. 2012;38(4):281–285. https://dx.doi.org/10.1016/j.ejso.2011.12.005
  32. Kruiff S., Bastiaannet E., Suurmeyer A.J., Hoekstra H.J. Detection of nodular metastases of melanoma; differences in detection between elderly and young patients do not affect survival. Ann Surg Oncol. 2010;17(11):3008–3014. https://dx.doi.org/10.1245/s10434-010-1085-1
  33. Xing Y., Bronstein Y., Ross M.I. et al. Contemporary diagnostic imaging and recommendations for diagnosis and follow-up of patients with melanoma: a meta-analysis. J Natl Cancer Inst. 2011;103(2):129–142. https://dx.doi.org/10.1093/jnci/djq455
  34. Ribero S., Podlipnik S., Osella-Abate S. et al. Ultrasound-based follow-up does not increase the survival of patients with early-stage melanoma: a comparative cohort study. Eur J Cancer. 2017;85:59–66. https://dx.doi.org/10.1016/j.ejca.2017.07.051
  35. Riquelme-McLaughlin S., Podlipnik S., Bosch-Amate X. et al. Diagnostic accuracy of imaging studies for initial staging of T2b to T4b melanoma patients: a cross-sectional study. J Am Acad Dermatol. 2019;81(6):1330–1338. https://dx.doi.org/10.1016/j.jaad.2019.05.076
  36. Podlipnik S., Carrera S., Sanchez M. et al. Performing diagnostic tests in an intensive follow-up protocol for American Joint Committee on Cancer (AJCC) patients with stages IIB, IIC and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol. 2016;75(3):516–524. https://dx.doi.org/10.1016/j.jaad.2016.02.1229
  37. Podlipnik S., Moreno-Ramirez D., Carrera S. et al. Cost-effectiveness analysis of an imaging strategy for intensive follow-up of patients with the American Joint Committee on Stage IIB Cancer, Malignant Melanoma IIC and III. Br J Dermatol. 2019;180(5):1190–1197. https://dx.doi.org/10.1111/bjd.16833

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Bionika Media, 2025